Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS ...

A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

Icotrokinra was safe and effective for improving skin clearance among patients with at least moderate psoriasis in high-impact areas.

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...

The Johnson & Johnson JNJ stock has risen 4.4% in six months, adding more than $15 billion to its market value. J&J faces ...

Icotrokinra’s market potential is even more substantial, with some analysts modeling peak sales exceeding $5 billion. This aligns with projections from Protagonist’s partner, ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated ...

Meanwhile, BTIG reaffirmed its Buy rating and an $82 target, highlighting icotrokinra’s potential in the adolescent psoriasis market, where existing treatments lack approval for those under 18.

Meanwhile, BTIG reaffirmed its Buy rating and an $82 target, highlighting icotrokinra’s potential in the adolescent psoriasis market, where existing treatments lack approval for those under 18. BMO ...

The study showed promising outcomes in adolescents, with icotrokinra outperforming existing oral therapies and demonstrating a favorable safety profile. BMO Capital Markets also raised its price ...

There was little difference between icotrokinra and placebo on safety, with 49.3% of those on the IL-23 inhibitor and 49.1% of the placebo group reporting a treatment-emergent adverse event (TEAE ...

Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting.